References

American Cancer Society
Evolution of cancer treatments: Chemotherapy
Accessed 4/10/15
http://www.cancer.org/cancer/cancerbasics/thehistoryofcancer/the-history-of-cancer-cancer-treatment-chemo

Baquiran, D.C. (2001). Cancer Chemotherapy Handbook. (2nd Ed. ) Philadelphia: Lippincott. 85-140.

Barr S, Thomson S, Buck E, et al. (2008)
Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.
Clinical & Experimental Metastasis. 2008;25:685–693

Bartlett, D; Liu, Z; Sathaiah, M; et al (2013)
Oncolytic viruses as therapeutic cancer vaccines.
Molecular Cancer 2013, 12:103 

Bender, C.B. In: Itano, J.K., & Taoka, K.N. (1998). Cancer chemotherapy agents. In: Itano, J.K., & Taoka, K.N. (1998). Core Curriculum in Oncology Nursing, 3rd Ed. Philadelphia: W.B. Saunders, 641-655.

Blagosklonny, M; Pardee, A. (2000)
The Restriction Point of the Cell Cycle
Madame Curie Bioscience Database [Internet]
Austin (TX): Landes Bioscience

Canadian Association of Nurses in Oncology
National Strategy for Chemotherapy Administration
STANDARDS AND COMPETENCIES FOR CANCER CHEMOTHERAPY NURSING PRACTICE
Accessed online 4/10/15
https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=156524

Cancer Management: A Multidisciplinary Approach: Medical, Surgical, & Radiation Oncology 7th Ed.Richard Pazdur, MD, Lawrence R. Coia, MD, William J. Hoskins, MD, and Lawrence D. Wagman, MD, FACS
SCP Oncology Group
Published 06/15/2003

Cancer multidrug resistance
Nature Biotechnology 18, IT18 - IT20 (2000)

Cancer Research UK
Mustard gas – from the Great War to frontline chemotherapy.
Accessed online 4/11/15
http://scienceblog.cancerresearchuk.org/2014/08/27/mustard-gas-from-the-great-war-to-frontline-chemotherapy/

Centers for Disease Control and Prevention
Workplace Safety & Health Topics
HAZARDOUS DRUG EXPOSURES IN HEALTH CARE
Accessed online 3/12/15
http://www.cdc.gov/niosh/topics/hazdrug/

Centers for Disease Control and Prevention
National Institute for Occupational Safety and Health (NIOSH)
Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Health Care Settings (2004)
Accessed online 3/12/15
http://www.cdc.gov/niosh/docs/2004-165/pdfs/2004-165.pdf

Christman, J. (2002)
5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy.
Oncogene. 12 August 2002, Volume 21, Number 35, Pages 5483-5495
http://www.nature.com/onc/journal/v21/n35/full/1205699a.html

Dear. F; McGeechan K; Jenkins MC, et al. (2013)
Combination versus sequential single agent chemotherapy for metastatic breast cancer.
Editorial Group: Cochrane Breast Cancer Group
Published Online: 18 DEC 2013

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Center for Disease Control and Prevention
National Institute for Occupational Safety and Health
DHHS (NIOSH) Publication Number 2004−165

DrugBank
Accessed online 5/30/2015
http://www.drugbank.ca/drugs/DB01168

Growenwald, S, et al. (1995). Comprehensive Cancer Nursing Review, (2nd ed). Boston: Jones and Barlett, 118-125.
Guy, J.L., & Ingram, B.A. (1996). Medical oncology: The agents. In: R. Mc Corkcle, et al. (Eds). Cancer Nursing: A Comprehensive Textbook. Philadelaphia: W.B. Saunders, 359-394.

Heine, G; Drozdenko, G; Grün, JR; Chang, HD; Radbruch, A; Worm, M.
Autocrine IL-10 promotes human B-cell differentiation into IgM- or IgG-secreting plasmablasts.
European Journal of Immunology. 2014 Jun;44(6):1615-21.

Henderson, B. and Feigelson, H. (2000)
Hormonal carcinogenesis
Carcinogenesis (2000) 21 (3): 427-433.
Oxford University Press

Hochhauser, D
Cancer and its Management
John Wiley & Sons, Oct 3, 2014

Housman, G; Byler, S; Heerboth, S; et al. (2014)
Drug Resistance in Cancer: An Overview
Cancers 2014, 6, 1769-1792

Huber, R; Lucas, J; Gomez-Sarosi, L.; et al. (2014)
DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate ;cancer treatment resistance.
Oncotarget, Advance Publications December 10, 2014

Kiess W, Gallaher B.
Hormonal control of programmed cell death/apoptosis.
European Journal of Endocrinology 1998 May;138(5):482-91.

Kim HJ, Litzenburger BC, Cui X, et al. (2007).
Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail.
Molecular & Cellular Biology. 2007;27:3165–3175

Kuske, B; Naughton, C; Moore, K; et al. (2006)
Endocrine therapy resistance can be associated with high estrogen receptor a (ERa) expression and reduced ERa phosphorylation in breast cancer models.
Endocrine-Related Cancer (2006) 13 1121–1133

Maxon, J.H., & Wolk, J.E. (1998). Principles of preparation, administration, and disposal of antineoplastic agents. In: Itano, J.K., & Taoka, K.N. Core Curriculum in Oncology Nursing, 3rd Ed., Philadelphia: W.B. Saunders, 657-660
www.cancer/org
www.nci.nih.gov

Miller, D.R. (2006)
A tribute to Sidney Farber – the father of modern chemotherapy
British Journal of Haematology, 134, 20–26

Mini, E; Nobili, S; Caciagli, B; Landini, I; Mazzei, T.
Cellular pharmacology of gemcitabine
Annals of Oncology 17 (Supplement 5): v7–v12, 2006

NCCN Task Force Report: Oral Chemotherapy
Journal of the National Comprehensive Cancer Network, Volume 6, Supplement 3, March 2008
.

NIH National Cancer Institute
ABOUT CANCER
Biological Therapies for Cancer.
http://www.cancer.gov/about-cancer/treatment/types/immunotherapy/bio-therapies-fact-sheet#q1

NIOSH Study Finds Lack of Adherence to Safe Handling Guidelines for Administration of Antineoplastic Drugs.
NIOSH Update: September 26, 2014
http://www.cdc.gov/niosh/updates/upd-9-26-14.html

NIOSH - WORKPLACE SOLUTIONS
Personal Protective Equipment for Health Care Workers Who Work with Hazardous Drugs
Accessed online 4/9/15
http://www.cdc.gov/niosh/docs/wp-solutions/2009-106/pdfs/2009-106.pdf

Ohba, T; Cates, J; Cole, H; Slosky, D; et al.
Autocrine VEGF/VEGFR1 Signaling in a Subpopulation of Cells Associates with Aggressive Osteosarcoma
Molecular Cancer Research
August 2014 12; 1100

Otto, K; Vander Griend, D; Conzen,S; Szmulewitz, R. (2015)
Abstract 148: Glucocorticoid receptor-mediated cell survival following androgen receptor blockade in castrate-resistant prostate cancer.
Proceedings: AACR 103rd Annual Meeting 2012-- Mar 31-Apr 4, 2012; Chicago, IL
Journal of Cancer Research April 15, 2012 72;

Parker, W (2009)
Enzymology of Purine and Pyrimidine Antimetabolites Used in the Treatment of Cancer.
Chemical Reviews. 2009 Jul; 109(7): 2880–2893.

Robertson J, Blamey R. (2003)
The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women.
European Journal of Cancer. 2003 May;39(7):861-9

Schwab, M.
Encyclopedia of Cancer, Volume 1
Springer Science & Business Media, Sep 23, 2011

Shanie, E; Xu, W. (2010)
Selectively targeting estrogen receptors for cancer treatment.
Advanced drug delivery reviews. 2010;62(13):1265-1276

Shohara, R; Yamamoto, A; Takikawa, S; et al. (2012)
Mesenchymal stromal cells of human umbilical cord Wharton's jelly accelerate wound healing by paracrine mechanisms.
Cytotherapy 2012 Nov;14(10):1171-81

Swift, L; Golsteyn, R. (2014)
Genotoxic Anti-Cancer Agents and Their Relationship to DNA Damage, Mitosis, and Checkpoint Adaptation in Proliferating Cancer Cells .
International Journal of Molecular Sciences 2014, 15, 3403-3431

Thompson, E; Johnson, B. (2003)
Regulation of a Distinctive Set of Genes in Glucocorticoid-evoked Apoptosis in CEM Human Lymphoid Cells
The Endocrine Society
Accessed 6/22/15
http://www.endocrine.org/~/media/endosociety/Files/EP/RPHR/58/RPHR_vol_58_ch_08_regulation_
of_a_distinctive_set_of_genes.pdf

University of California - Davis
CHEMWIKI
Anti-Cancer Drugs II
Accessed online 5/26/15
http://chemwiki.ucdavis.edu/Biological_Chemistry/Drug_Activity/Anti-Cancer_Drugs_II

U.S. Food and Drug Administration
Prescribing information for SOMATULINE® DEPOT (lanreotide) INJECTION.http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022074s010lbl.pdf

Walsh, J; Karnes, W; Cuttitta, F; Walker, A.
Autocrine growth factors and solid tumor malignancy.
Western Journal of Medicine. 1991 Aug; 155(2): 152–163.

Yemelyanov, A; Czwornog, J; Chebotaev, D; etc. (2007)
Tumor suppressor activity of glucocorticoid receptor in the prostate.
Oncogene (2007) 26, 1885–1896.